The Ontario Superior Court has certified a class action for Canadians who took the quit-smoking drug Champix between April 2, 2007, and May 31, 2010, and allegedly suffered certain reactions, according to a press note issued by Canadian law firm Bruneau Group Inc. through PRNewswire.
The reactions listed in the press note were thoughts about suicide or dying; attempts to commit suicide; new or worse depression, anxiety or panic attacks; feeling very agitated or restless; acting aggressively, being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); abnormal thoughts or sensations; seeing or hearing things that are not there (hallucinations); feeling people are against you (paranoia); feeling confused; and other unusual changes in behaviors.
The lawsuit seeks compensation and alleges that, between April 2, 2007, and May 31, 2010, Pfizer Canada Inc. failed to adequately warn of the risk of certain psychiatric adverse events allegedly related to Champix.
Pfizer Canada Inc. denies the allegations and is defending the lawsuit.
Category: Breaking News